<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01471990</url>
  </required_header>
  <id_info>
    <org_study_id>H-1-2011-023</org_study_id>
    <nct_id>NCT01471990</nct_id>
  </id_info>
  <brief_title>Effect of PACAP38/VIP on Migraineurs Measured by Magnetic Resonance</brief_title>
  <official_title>The Effect of PACAP38 and VIP on Migraine Patients Assessed by a 3-Tesla MR Scanner</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Glostrup University Hospital, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bispebjerg Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Hospital, Gentofte, Copenhagen</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lundbeck Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Cool Sorption Foundation of 1988</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Glostrup University Hospital, Copenhagen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to examine and compare the effect of pituitary adenylate
      cyclase-activating polypeptide-38 (PACAP38) and vasoactive intestinal polypeptide (VIP) on
      intracranial arteries and neuronal activity in patients with migraine without aura using a
      high resolution magnetic resonance imaging (MRI), including MR angiography (MRA) and
      functional MRI (fMRI).

      MRA will be used to detect changes in intracranial artery circumferences before and after
      PACAP38 and VIP.

      fMRI will be used oo detect changes in blood-oxygenation-level-dependent-signal
      (BOLD-signal).

      PACAP38 but not VIP induces migraine like attacks in migraine patients. The migraine specific
      drug sumatriptan will be given to relieve pain and the effect will also be registered using
      MRA and fMRI.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Comparison between PACAP38 and VIP induced changes in intracranial artery circumference before and after infusions</measure>
    <time_frame>Baseline, 20 minutes, 2 hours and 5 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Headache scores</measure>
    <time_frame>24 hours</time_frame>
    <description>hospital and post hospital phase</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between PACAP38 and VIP induced changes in BOLD response</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in intracranial artery circumference before and after injection of sumatriptan</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison between PACAP38 and VIP induced changes in brain structure</measure>
    <time_frame>5 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Migraine Without Aura</condition>
  <arm_group>
    <arm_group_label>PACAP38</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>VIP</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pituitary Adenylate Cyclase-Activating Polypeptide-38</intervention_name>
    <description>10 pmol/kg/min over 20 mins</description>
    <arm_group_label>PACAP38</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vasoactive Intestinal Peptide</intervention_name>
    <description>8 pmol/kg/min over 20 mins</description>
    <arm_group_label>VIP</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy migraine patient without aura

          -  Age 18-40

          -  Weight 50-100 kg

          -  Fertile women must use safe contraceptives

        Exclusion Criteria:

          -  Tension type headache more than 5 days per month

          -  Other primary headaches

          -  Daily use of medication except contraceptives

          -  Drug taken within 4 times the half life for the specific drug except contraceptives

          -  Pregnant or lactating women

          -  Exposure to radiation within the last year

          -  Hypotension or hypertension

          -  Cardiovascular or cerebrovascular disease

          -  Mental illness or substance abuse

          -  Other significant conditions determined by the examining doctor

          -  Contraindications to MRI scan

          -  Headache within the last 48 hours before start of trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Faisal Amin, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Centre and Department of Neurology, Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Glostrup Hospital, Faculty of Health Sciences, University of Copenhagen</name>
      <address>
        <city>Glostrup</city>
        <zip>DK-2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 9, 2011</study_first_submitted>
  <study_first_submitted_qc>November 10, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 16, 2011</study_first_posted>
  <last_update_submitted>August 28, 2012</last_update_submitted>
  <last_update_submitted_qc>August 28, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 29, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Glostrup University Hospital, Copenhagen</investigator_affiliation>
    <investigator_full_name>Faisal Mohammad Amin</investigator_full_name>
    <investigator_title>medical doctor</investigator_title>
  </responsible_party>
  <keyword>PACAP38</keyword>
  <keyword>MMA</keyword>
  <keyword>migraine</keyword>
  <keyword>angiography</keyword>
  <keyword>VIP</keyword>
  <keyword>vasodilatation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Migraine without Aura</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pituitary Adenylate Cyclase-Activating Polypeptide</mesh_term>
    <mesh_term>Vasoactive Intestinal Peptide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

